Chemical Compound Review:
Flosequinanum 7-fluoro-3-methoxysulfanyl-1- methyl...
Synonyms:
SureCN1651722, AC1L1F33, AC1Q4GF7, AC1Q4NY5, UNII-6NB119DLU7
- Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET). Massie, B.M., Berk, M.R., Brozena, S.C., Elkayam, U., Plehn, J.F., Kukin, M.L., Packer, M., Murphy, B.E., Neuberg, G.W., Steingart, R.M. Circulation (1993)
- Effect of flosequinan in patients with acute-onset heart failure complicating acute myocardial infarction. Schneeweiss, A., Wynne, R.D., Marmor, A. Crit. Care Med. (1989)
- Effect of flosequinan on ischaemia-induced arrhythmias and on ventricular cyclic nucleotide content in the anaesthetized rat. Jones, R.B., Frodsham, G., Dickinson, K., Foster, G.A. Br. J. Pharmacol. (1993)
- Cardiovascular effects of the novel arteriovenous dilator agent, flosequinan in conscious dogs and cats. Sim, M.F., Yates, D.B., Parkinson, R., Cooling, M.J. Br. J. Pharmacol. (1988)
- Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study. Packer, M., Narahara, K.A., Elkayam, U., Sullivan, J.M., Pearle, D.L., Massie, B.M., Creager, M.A. J. Am. Coll. Cardiol. (1993)
- Sustained hemodynamic response to flosequinan in patients with heart failure receiving angiotensin-converting enzyme inhibitors. Gottlieb, S.S., Kukin, M.L., Penn, J., Fisher, M.L., Cines, M., Medina, N., Yushak, M., Taylor, M., Packer, M. J. Am. Coll. Cardiol. (1993)
- Sulphoxide reduction by rat intestinal flora and by Escherichia coli in vitro. Lee, S.C., Renwick, A.G. Biochem. Pharmacol. (1995)
- A comparison of the metabolic effects of flosequinan and propranolol in patients with non-insulin-dependent diabetes mellitus. Lewis, H.M., Kendall, M.J., Wright, A.D., Bratty, J.R., Maxwell, S. Journal of clinical pharmacy and therapeutics. (1991)
- Effect of flosequinan on exercise capacity and symptoms in severe heart failure. Elborn, J.S., Stanford, C.F., Nicholls, D.P. British heart journal. (1989)
- Flosequinan, a new vasodilator: systemic and coronary hemodynamics and neuroendocrine effects in congestive heart failure. Cavero, P.G., De Marco, T., Kwasman, M., Lau, D., Liu, M., Chatterjee, K. J. Am. Coll. Cardiol. (1992)
- Positive inotropic and lusitropic effects of intravenous flosequinan in patients with heart failure. Burstein, S., Semigran, M.J., Dec, G.W., Boucher, C.A., Fifer, M.A. J. Am. Coll. Cardiol. (1992)
- Haemodynamic and neurohumoral effects of flosequinan in severe heart failure: similarities and differences compared with intravenous nitroglycerin therapy. Dakak, N., Makhoul, N., Merdler, A., Yechiely, H., Kahana, L., Halon, D.A., Schneeweiss, A., Lewis, B.S. Eur. Heart J. (1993)
- The electrophysiological effects of flosequinan. Bashir, Y., O'Nunain, S., Paul, V.E., Butrous, G.S., Ward, D.E., Camm, A.J. Eur. Heart J. (1991)
- Acute and chronic effects of flosequinan on resting and exercise haemodynamics in congestive heart failure. Thomas, P., O'Gorman, D.J., Sheridan, D.J. British journal of clinical pharmacology. (1993)
- Differential inotropic effects of flosequinan in ventricular muscle from normal ferrets versus patients with end-stage heart failure. Perreault, C.L., Hague, N.L., Loh, E., Hunneyball, I.M., Sim, M.F., Morgan, J.P. Br. J. Pharmacol. (1992)
- Flosequinan, a vasodilator with a novel mechanism of action. Resnick, M.S., Maitland, L.A., Morgan, K.G. Br. J. Pharmacol. (1991)
- Effect of flosequinan upon isoenzymes of phosphodiesterase from guinea-pig cardiac and vascular smooth muscle. Frodsham, G., Jones, R.B. Eur. J. Pharmacol. (1992)
- A double-blind, parallel-group comparison of flosequinan and enalapril in the treatment of chronic heart failure. Silke, B., Tennet, H., Fischer-Hansen, J., Keller, N., Heikkila, J., Salminen, K. Eur. Heart J. (1992)
- Novel drugs and current therapeutic approaches in the treatment of heart failure. Bonarjee, V.V., Dickstein, K. Drugs (1996)
- Chiral inversion of drug: role of intestinal bacteria in the stereoselective sulphoxide reduction of flosequinan. Kashiyama, E., Yokoi, T., Todaka, T., Odomi, M., Kamataki, T. Biochem. Pharmacol. (1994)
- Cytochrome P450 responsible for the stereoselective S-oxidation of flosequinan in hepatic microsomes from rats and humans. Kashiyama, E., Yokoi, T., Odomi, M., Funae, Y., Inoue, K., Kamataki, T. Drug Metab. Dispos. (1997)
- Relation of circulating cardiac myosin light chain 1 isoform in stable severe congestive heart failure to survival and treatment with flosequinan. Hansen, M.S., Stanton, E.B., Gawad, Y., Packer, M., Pitt, B., Swedberg, K., Rouleau, J.L. Am. J. Cardiol. (2002)
- Exercise tolerance in patients with heart failure--how should it be measured? Cowley, A.J., Fullwood, L., Stainer, K., Hampton, J.R. Eur. Heart J. (1991)
- The effects of flosequinan on regional blood flow in normal man. Scott, R.A., Woods, K.L., Barnett, D.B. British journal of clinical pharmacology. (1991)
- Importance of assessing changes in ventricular response to atrial fibrillation during evaluation of new heart failure therapies: experience from trials of flosequinan. Massie, B.M., Shah, N.B., Pitt, B., Packer, M. Am. Heart J. (1996)
- Effects of low-dose flosequinan on left ventricular systolic and diastolic chamber performance. Starling, M.R. Am. Heart J. (1994)